Monte Rosa Therapeutics, Inc. Retained Earnings
Monte Rosa Therapeutics, Inc. (GLUE) had Retained Earnings of -$565.11 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$565.11M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$521.72M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$477.21M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$431.08M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$565.11M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$521.72M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$477.21M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$431.08M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$404.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$391.70M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$438.59M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$452.02M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$428.17M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$397.86M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$365.89M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$332.64M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$297.75M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$262.57M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$230.54M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$199.75M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$172.44M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$145.97M 10-Q · filed 2022-05-11 |
| 2021-12-31 | -$122.03M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$98.59M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$78.76M 10-Q · filed 2021-08-12 |
| 2020-12-31 | -$48.08M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |